Epigenetic state determines the in vivo efficacy of STING agonist therapy

Epigenetic state determines the in vivo efficacy of STING agonist therapy

STING agonists have shown limited efficacy in early-phase clinical trials despite promising pre-clinical data. This study shows the potential clinical relevance of the use of combination STING agonists and demethylating agent therapies to induce the expression of STING.

Bibliographic Details
Main Authors: Rana Falahat, Anders Berglund, Patricio Perez-Villarroel, Ryan M. Putney, Imene Hamaidi, Sungjune Kim, Shari Pilon-Thomas, Glen N. Barber, James J. Mulé
Format: Article
Language:English
Published: Nature Portfolio 2023-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-37217-1

Internet

https://doi.org/10.1038/s41467-023-37217-1

Similar Items